ATE181332T1 - Vom gtpase-aktivierenden protein (gap) abgeleitete peptide sowie deren diagnostische und therapeutische verwendung - Google Patents

Vom gtpase-aktivierenden protein (gap) abgeleitete peptide sowie deren diagnostische und therapeutische verwendung

Info

Publication number
ATE181332T1
ATE181332T1 AT90914312T AT90914312T ATE181332T1 AT E181332 T1 ATE181332 T1 AT E181332T1 AT 90914312 T AT90914312 T AT 90914312T AT 90914312 T AT90914312 T AT 90914312T AT E181332 T1 ATE181332 T1 AT E181332T1
Authority
AT
Austria
Prior art keywords
peptides
ras
val
arg
gtpase
Prior art date
Application number
AT90914312T
Other languages
English (en)
Inventor
Francis P Mccormick
Gail L Wong
Paul G Polakis
Bonnie Rubinfeld
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE181332T1 publication Critical patent/ATE181332T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT90914312T 1989-08-21 1990-08-20 Vom gtpase-aktivierenden protein (gap) abgeleitete peptide sowie deren diagnostische und therapeutische verwendung ATE181332T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39691089A 1989-08-21 1989-08-21

Publications (1)

Publication Number Publication Date
ATE181332T1 true ATE181332T1 (de) 1999-07-15

Family

ID=23569088

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90914312T ATE181332T1 (de) 1989-08-21 1990-08-20 Vom gtpase-aktivierenden protein (gap) abgeleitete peptide sowie deren diagnostische und therapeutische verwendung

Country Status (8)

Country Link
EP (1) EP0491828B1 (de)
JP (1) JPH05500506A (de)
AT (1) ATE181332T1 (de)
AU (2) AU652724B2 (de)
CA (1) CA2065017A1 (de)
DE (1) DE69033166T2 (de)
IL (1) IL95441A0 (de)
WO (1) WO1991002749A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830684A (en) * 1988-08-10 1998-11-03 Chiron Corporation Native type II GAP, methods for purifying various GAPs and uses of GAPs to diagnose cancer
FR2690162B1 (fr) * 1992-04-21 1995-08-04 Rhone Poulenc Rorer Sa Peptides ayant une activite de facteur d'echange du gdp, sequences d'acides nucleiques codant pour ces peptides, preparation et utilisation.
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
IL116026A (en) * 1994-11-22 2005-08-31 Rhone Poulenc Rorer Sa Peptides capable of linking to the sh3 domain of gap, nucleotide sequences encoding the same, their preparation and uses
FR2727116B1 (fr) * 1994-11-22 1996-12-20 Rhone Poulenc Rorer Sa Peptides capables de se lier au domaine sh3 de la proteine gap, sequences nucleotidiques codant pour ces peptides, leur preparation et utilisation
FR2734266B1 (fr) * 1995-05-16 1997-06-20 Rhone Poulenc Rorer Sa Peptides capables de se lier au domaine sh3 de la proteine gap sequences nucleotidiques codant pour ces peptides, leur preparation et utilisation
US6312941B1 (en) * 1997-11-26 2001-11-06 The Regents Of The University Of Michigan Compositions and methods for identifying signaling pathway agonists and antagonists
US20020137911A1 (en) * 2000-08-03 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
EP4013865A4 (de) * 2019-08-14 2023-08-23 ModernaTX, Inc. Verfahren zur reinigung von nachgelagerten produkten einer in-vitro-transkription

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU627764B2 (en) * 1988-07-08 1992-09-03 Cetus Corp Gap gene sequences and diagnostic uses thereof
JPH04500122A (ja) * 1988-08-12 1992-01-09 プロジェンクス・インコーポレイテッド 蛋白リガンドに対するポリペプチド誘発モノクローナル受容体
CA2006496A1 (en) * 1988-12-22 1990-06-22 Mark C. Fishman Mammalian gap-43 compositions and methods of use

Also Published As

Publication number Publication date
AU6424790A (en) 1991-04-03
EP0491828B1 (de) 1999-06-16
AU652724B2 (en) 1994-09-08
JPH05500506A (ja) 1993-02-04
DE69033166T2 (de) 1999-12-23
AU8034694A (en) 1995-02-16
IL95441A0 (en) 1991-06-30
CA2065017A1 (en) 1991-02-22
DE69033166D1 (de) 1999-07-22
WO1991002749A1 (en) 1991-03-07
EP0491828A1 (de) 1992-07-01

Similar Documents

Publication Publication Date Title
Michaelsen et al. Primary structure of the" hinge" region of human IgG3. Probable quadruplication of a 15-amino acid residue basic unit.
DE3587863T2 (de) Mit thrombozyten verwandter wachstumregulator.
Graziadei et al. Co-capping of ras proteins with surface immunoglobulins in B lymphocytes
Carter et al. Porcine aortic endothelial gap junctions: identification and permeation by caged InsP3
NO913211L (no) Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer.
NO985150L (no) Antigenbindingsfragmenter som spesifikt detekterer cancerceller, nukleotider som koder fragmentene samt anvendelse derav for profylakse og deteksjon av cancere
DE602005026143D1 (de) Erkennung eines erhöhten spiegels von her-2/neu-proteinen in zirkulierenden krebszellen und dessen behandlung
DE68928069D1 (de) Anti-T-Zell Rezeptordeterminanten zur Behandlung von Autoimmunkrankheiten
HUP0101501A2 (hu) Javított termelhetőségű FAP alfa-specifikus antitest
BG99605A (en) Antagonists of the growth factor or endothelial cells of the circulatory system
MX9705349A (es) Anticuerpo monoclonal 1a7 y su uso para el tratamiento de melanona y carcinoma de celulas pequeñas.
ATE181332T1 (de) Vom gtpase-aktivierenden protein (gap) abgeleitete peptide sowie deren diagnostische und therapeutische verwendung
DE3789781T2 (de) Antigene, Antikörper und Verfahren zur Identifizierung humaner metastatischer Tumoren und Zellinien zur Herstellung dieser Antikörper.
ATE151078T1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
Mikhailova et al. Immunoregulatory properties of hexapeptide isolated from porcine bone marrow cell culture
AU2256097A (en) A g protein-coupled receptor with an enlarged extracellular domain
DE69329656D1 (de) Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase-peptidantigenen exprimierenden zellen
DE69229394D1 (de) Zusammensetzungen und methoden zur behandlung von kleinzell und nicht-kleinzell lungenkrebsen
Schwartz et al. Secretion of adrenocorticotrophin (ACTH) and ACTH precursors in ovine anterior pituitary cells: actions of corticotrophin-releasing hormone, arginine vasopressin and glucocorticoids
ATE296316T1 (de) Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung
ATE75754T1 (de) Monoklonale antikoerper gegen atriale, natriurethische peptide.
Andre et al. Merosin is synthesized by thyroid cells in primary culture irrespective of cellular organization
Michaelsen Evidence of 15 S–S Bridges in the Hinge Region of Human 530
FR2571146B1 (fr) Antigenes carcino-foetaux du pancreas humain et un procede de purification, antiserum contre ces antigenes et son procede de preparation et compositions diagnostiques les contenant
Goldrosen et al. Structural and immunological studies of two IgGl-λ myeloma proteins from a single patient

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties